| scholarly article | Q13442814 |
| P50 | author | Yusuke Okuma | Q41393127 |
| P2093 | author name string | Kaoru Kubota | |
| Yasuhiro Kato | |||
| Akihiko Gemma | |||
| Masahiro Seike | |||
| Yukio Hosomi | |||
| Tatsuru Okamura | |||
| Kageaki Watanabe | |||
| Makiko Yomota | |||
| Shoko Kawai | |||
| P2860 | cites work | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial | Q27851712 |
| Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial | Q27852787 | ||
| AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer | Q27853158 | ||
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR | Q29547545 | ||
| Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study | Q33436083 | ||
| Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors. | Q33897441 | ||
| Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors | Q35587238 | ||
| Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib | Q36372611 | ||
| Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. | Q37379113 | ||
| Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer? | Q38845975 | ||
| An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. | Q40384809 | ||
| Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer | Q41646881 | ||
| The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer | Q42378535 | ||
| A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). | Q42611912 | ||
| First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy | Q46118410 | ||
| Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial | Q47257690 | ||
| Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer | Q47450132 | ||
| Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. | Q48020812 | ||
| High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer. | Q51745636 | ||
| Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. | Q51802507 | ||
| Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort. | Q52678697 | ||
| Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors. | Q52839850 | ||
| Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small cell lung cancer: AURA3 trial. | Q54114179 | ||
| Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. | Q54368639 | ||
| Differential microRNA expression profiles between young and old lung adenocarcinoma patients. | Q55243832 | ||
| Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer | Q88954090 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 2350-2360 | |
| P577 | publication date | 2019-06-01 | |
| P1433 | published in | Journal of thoracic disease | Q26841814 |
| P1476 | title | Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors | |
| P478 | volume | 11 |
| Q92424714 | Impact of clinical features of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients on osimertinib efficacy |
| Q91792623 | The impact of age and performance status on the efficacy of osimertinib in patients with EGFR T790M-positive non-small cell lung cancer |
Search more.